TY - JOUR
KW - Adult
KW - Age Factors
KW - Analgesics, Opioid/pharmacology
KW - Anti-Anxiety Agents/administration & dosage
KW - Anxiety/drug therapy/psychology
KW - Buprenorphine/therapeutic use
KW - Craving/drug effects
KW - Female
KW - Humans
KW - Male
KW - Narcotic Antagonists/pharmacology
KW - Opiate Substitution Treatment/methods/psychology
KW - Opioid-Related Disorders/drug therapy/psychology
KW - Risk Factors
KW - Secondary prevention
KW - Sex Factors
KW - Substance Withdrawal Syndrome/prevention & control/psychology
KW - Treatment Failure
KW - Young Adult
AU - C. Baxley
AU - J. Weinstock
AU - P. J. Lustman
AU - A. A. Garner
A1 - 
BT - Experimental and clinical psychopharmacology
C5 - Opioids & Substance Use
CP - 1
CY - United States
DO - 10.1037/pha0000215
IS - 1
JF - Experimental and clinical psychopharmacology
PP - United States
PY - 2019
SN - 1936-2293; 1064-1297
SP - 64
EP - 77
EP - 
T1 - The influence of anxiety sensitivity on opioid use disorder treatment outcomes
T2 - Experimental and clinical psychopharmacology
TI - The influence of anxiety sensitivity on opioid use disorder treatment outcomes
U1 - Opioids & Substance Use
U2 - 30080059
U3 - 10.1037/pha0000215
VL - 27
VO - 1936-2293; 1064-1297
Y1 - 2019
ER -